CanSino Biologics Inc (CanSinoBIO) said China's drug regulator, the National Medical Products Administration, accepted its COVID-19 vaccine application on Wednesday.
The single-dose vaccine, developed by CanSinoBIO and a team led by Chen Wei, a researcher from the Beijing-based Academy of Military Medical Sciences, will become the country's third locally developed shot allowed for conditional use by the general public if approved.
